Anti-inflammatory Composition Comprising Colloidal Silver and Plant Extracts

Abstract

The present invention relates to a composition comprising at least colloidal silver, an extract of Sambucus Nigra, an extract of Primula flowers with calyx (Primulae flos cum calycibus), and / or an extract of Hypericum perforatum, and an extract of Pelargonium sidoides, for use as a medicament in the prevention and / or treatment of inflammation. According to one embodiment, the composition is used for the prevention and / or treatment of inflammation caused by Staphylococcus aureus.

Description

[Technical Field]

[0001] The present invention relates to a composition comprising at least silver in colloidal form, an extract of Sambucus Nigra, an extract of Hypericum perforatum, and an extract of Pelargonium sidoides for use as a medicament in the prevention and / or treatment of inflammation. According to one embodiment, the composition is used for the prevention and / or treatment of inflammation caused by Staphylococcus aureus.

[0002] The present invention relates in particular to the field of prevention and treatment of inflammation associated with Staphylococcus aureus. [Background technology]

[0003] The therapeutic properties of silver were already known in ancient Greece, when it was known that households that used silverware for eating had a lower incidence of infectious diseases. Silver exhibits important antibacterial properties, as only a 1 part in 100 million concentration of elemental silver in solution is required for effective antibacterial action. It is also well known that silver ions or free radicals are the active antibacterial agents.

[0004] To make silver water-soluble, it is necessary to use its colloidal ionic form (a suspension of very fine silver particles in water), which was first obtained in 1920 by a hydrolysis process using two pure silver electrodes immersed in demineralized or distilled water across which a potential difference is applied.

[0005] Before the advent of antibiotics in 1938, colloidal silver obtained in this way was prescribed for a variety of illnesses and infections, and in fact was proven effective against over 650 different pathogens.

[0006] Colloidal silver can actually improve immune system function because it acts as a catalyst by inactivating certain enzymes necessary for the metabolism of many bacterial, fungal, and viral species.

[0007] This success is due to the fact that it is a safe preservative; in fact, when used in colloidal form, silver is absorbed into the tissues so slowly that it does not produce any toxic effects. It can therefore be taken orally and form part of a preparation that can be taken daily by adults and children without the risk of developing intolerance, even with prolonged use.

[0008] Colloidal silver is primarily used in dermatology as an antiseptic to treat certain types of lesions, but is also known for its use as a water purifying agent and as a preservative in the cosmetics industry.

[0009] However, colloidal silver is not effective against all fungi, viruses, and bacteria.

[0010] Staphylococcus aureus is the main pathogen responsible for various bacterial skin infections (Liu et al., 2018; Tatiya-Aphiradee et al., 2019). This bacterium is the most frequently encountered staphylococcal strain in human and animal pathology. Together with Escherichia coli, this bacterium shares the sad privilege of being the top pathogenic microorganism responsible for nosocomial infections. In France, S. aureus is also the top bacterium responsible for food poisoning.

[0011] Inflammation is considered a host defense response against two conditions: pathological conditions or pathogens (Medzhitov, 2008; Gu-nalan et al., 2014; Greten & Grivennikov, 2019; Agarwal & Shanmugam, 2020). It is well known that prolonged inflammation can lead to the development of rheumatoid arthritis, intestinal inflammatory diseases, asthma, and pancreatitis (Mueller et al., 2010), as well as predisposition to cancer (Agarwal & Shanmugam, 2020). Increased cytokine levels, cytokine receptors, adhesion molecules, immunomodulators, and several other mediators constitute key mechanisms of inflammation (Gunalan et al., 2014). Because chronic inflammation can have irreversible consequences, numerous studies have focused on developing anti-inflammatory products. Unfortunately, many pharmaceuticals available on the market are associated with undesirable side effects.

[0012] It is well known that the IL-1 family is involved in acute and chronic inflammation (Kolb et al., 2001) and thus plays an important role in regulating inflammatory processes (Sims and Smith, 2010). The IL-1 gene family is characterized by three components: IL-1α, IL-1β, and the IL-1 receptor antagonist (IL-1RA) (Dinarello, 1997). IL-1β, released after proteolytic cleavage, is likely involved in inflammatory processes (Kolb et al., 2001), because its overexpression and the resulting inflammatory cascade can lead to the development of autoimmune diseases (Pathak et al., 2011). Given the pathophysiological relevance of IL-1β, much research has focused on developing drugs and products targeting this interleukin (Peiro et al., 2017). To date, several drugs have been approved, including anakinra, rilonacept, and canakinumab ( Peiro et al., 2017 ).

[0013] Furthermore, overexpression and upregulation of IL-8 have been reported to be associated with multiple cancers, including breast cancer (Singh et al., 2013). Meanwhile, studies have noted a significant increase in IL-8 levels in postmenopausal women suffering from osteoporosis and bone loss (Al-Daghri et al., 2014). Therefore, reducing this marker could provide significant progress in addressing these health issues. Summary of the Invention [Problem to be solved by the invention]

[0014] Thus, there remains a need for effective alternatives to existing anti-inflammatory compositions that have fewer associated side effects. In particular, there continues to be a need for therapeutic and prophylactic treatments of inflammation, particularly inflammation associated with infections caused by Staphylococcus aureus. [Means for solving the problem]

[0015] The applicant has unexpectedly discovered that by combining colloidal silver with a number of plant extracts, it is possible to obtain a composition that is effective in preventing and / or treating inflammation, particularly inflammation caused by Staphylococcus aureus. Indeed, the applicant has confirmed that the composition according to the invention has the ability to reduce the production of inflammatory cytokines.

[0016] explanation Thus, according to a first aspect, the present invention relates to a composition for use as a medicament for the prevention and / or treatment of inflammation, comprising: - Colloidal form of silver - Elderberry extract - Hypericum perforatum extract - Pelargonium sidoides extract.

[0017] By ionic colloidal silver is understood, according to the invention, very fine silver particles suspended in water.

[0018] Preferably, the silver in colloidal form has a particle size of 0.1 to 30 nanometers.

[0019] Preferably, the composition for use according to the invention contains: - 20 mg to 250 mg of silver in colloidal form per liter of composition.

[0020] By convention, 1 mg of silver is generally considered to correspond to 1 ppm in 1 liter of solution, or 20 mg to 250 mg per liter of solution.

[0021] Sambucus nigra or black elderberry is a shrub-like plant of the honeysuckle family. The extracts obtained from this plant are obtained from its flowers or its fruits and are dry, aqueous and / or alcoholic extracts.

[0022] Preferably, the composition for use according to the invention contains: - 0.3 to 5% by weight of an extract of elderberry.

[0023] Hypericum perforatum, more commonly known as St. John's wort, is a perennial herbaceous plant in the family Garciniae. The extract can be obtained from the plant or flower tips, which can be crushed in water and / or alcohol as needed.

[0024] Preferably, the composition for use according to the invention contains: - 0.5 to 11% by weight of a composition of extract of St. John's wort.

[0025] Pelargonium sidoides or Umkaloabo is a plant native to South Africa. This plant extract can take the form of a dry, aqueous and / or alcoholic extract of the root or other parts of the plant.

[0026] Preferably, the composition for use according to the invention contains: - 1 to 6% by weight of a composition of Pelargonium sidoides extract.

[0027] By "treatment" is understood, according to the present invention, the administration of a composition according to the present invention to a patient in order to help the patient recover from the disease and reduce its symptoms, in this case inflammation within the scope of the present invention, preferably inflammation associated with infection by Staphylococcus aureus.

[0028] By "prevention" is understood, according to the present invention, the application of a composition according to the present invention to an individual or patient in order to prevent the onset or spread of a lesion, in this case inflammation within the scope of the present invention, preferably inflammation associated with an infection by Staphylococcus aureus.

[0029] Inflammation is the body's immune defense response to an attack. It can be acute or chronic. Clinical signs of inflammation include pain (throbbing), redness, swelling (edema), warmth, and impaired function. Histologically, acute inflammation is characterized by localized vascular degeneration (vasodilation, increased permeability, and edema with slowed blood flow), followed by a concentration of circulating leukocytes, first granulocytes and then monocytes, with marginal migration, adhesion to endothelial cells, extravasation, phagocytosis of foreign bodies and cellular and tissue debris, and, in some cases, pus formation. The course of the inflammatory response varies. In acute inflammation, after removal of the causative agent, mononuclear phagocytes (monocytes, macrophages, histiocytes, etc.) clean up the inflamed area, either resulting in a non-surviving "healing" process or helping to replace tissue destroyed by fibrosis and scarring without functional recovery. In other cases, in the absence of elimination of the cause or due to defects in certain tissue defense mechanisms, the inflammation becomes chronic and is characterized by the formation of inflammatory infiltrates, generally mixed (granulocytes, histiocytes-macrophages, lymphocytes, as well as giant cells and epithelioid cells), accompanied by angiogenic phenomena and, in particular, tissue remodeling processes (combining destructive and remodeling phenomena), with a significant proliferation of fibroblasts in particular.

[0030] Inflammatory responses involve many cell types (mononuclear and polynuclear phagocytes, lymphocytes, platelets, but also tissue innate cells and endothelial cells) and humoral mediators (proteins of the complement, contact system, and hemostatic pathways), all of which are therapeutic targets. Finally, most inflammatory responses result in a systemic response characterized by elevated plasma protein concentrations of so-called acute-phase proteins (e.g., C-reactive protein, serum amyloid A protein, multiple α-1-globulins, specific complement components, fibrinogen, and haptoglobin) and decreased concentrations of other proteins, such as albumin, transferrin, fibronectin, and apoprotein A-1. Inflammatory responses also involve interleukins, including the IL-1 family (IL-1α, IL-1β, and IL-1 receptor antagonist (IL-1RA) (Dinarello, 1997)), which play an important role in regulating the inflammatory process (Sims and Smith, 2010). IL-8 is also an interleukin known to be involved in inflammation.

[0031] The compositions used according to the invention make it possible to reduce the production of inflammatory cytokines, in particular IL-8, IP-10, IL-1β and IL-6.

[0032] According to one embodiment, the composition for use according to the invention contains: - 20 mg to 250 mg of colloidal silver per liter of composition - 0.3 to 5% by weight of elderberry extract - 0.5 to 11% by weight of a composition containing an extract of St. John's wort - 1 to 6% by weight of a composition of Pelargonium sidoides extract.

[0033] According to one embodiment, the composition for use according to the invention further contains: - Silver in ionic form.

[0034] By ionic silver is understood, according to the invention, silver whose particles are dissolved in water, as opposed to colloidal silver, whose particles are suspended in water.

[0035] According to one embodiment, the composition for use according to this latter embodiment contains: - The total amount of silver per liter of composition is 20mg to 250mg, distributed as follows: i. 70-99.99% of the total weight of silver in colloidal form ii. Silver in ionic form, 0.01 to 30% of the total weight of silver.

[0036] By total silver is understood according to the invention the total amount of silver contained in the composition according to the invention, whatever its form.

[0037] According to one embodiment, the composition used contains: -The total amount of silver per liter of composition is 20 mg to 250 mg, distributed as follows: i. 70-99.99% of the total weight of silver in colloidal form ii. 0.01 to 30% of the total weight of silver in ionic form - 0.3 to 5% by weight of elderberry extract - 0.5 to 11% by weight of a composition containing an extract of St. John's wort - 1 to 6% by weight of a composition of Pelargonium sidoides extract.

[0038] According to one embodiment, the composition for use according to the invention further contains: - Echinacea extract, and / or - Propolis, and / or - Artemisia extract, and / or - extract of Allium sativum, and / or - Extract of Primula flowers with calyx (Primulae flos cum calycibus).

[0039] Primula flowers with calyx or Primula japonica is a perennial plant of the Primulaceae family. The extract is obtained by crushing the flowers and / or calyx of this plant in water and / or alcohol as needed. These extracts can also be dried extracts.

[0040] Preferably, the composition for use according to the invention contains: - 1 to 9% by weight of an extract of primula flowers with calyx.

[0041] Echinacea refers to a genus of plants in the Asteraceae family. The extract may be in the form of a dry, aqueous and / or alcoholic extract produced from the root, the whole plant, or the aerial parts.

[0042] Preferably, the composition for use according to the invention contains: - 0.01 to 8% by weight of an Echinacea extract.

[0043] Allium sativum, the plant more commonly known as "garlic," is a species of perennial plant. Its extracts take the form of dried, aqueous and / or alcoholic extracts, or extracts of aged garlic.

[0044] Preferably, the composition for use according to the invention contains: - 0.01 to 10% by weight of an Allium sativum extract.

[0045] "Propolis" is a product derived from plant resins and exudates, secreted by plants or produced by bees from plant resins and waxes. Because propolis depends on the species of plant from which it is produced, standardized propolis is produced and is often defined by color. Preferably, the present invention uses yellow, green, or red propolis. The propolis can be provided in the form of dried, purified, aqueous, and / or alcoholic extracts.

[0046] Preferably, the composition for use according to the invention contains: - 0.01 to 7% by weight of a propolis composition.

[0047] Artemisia, or mugwort, is a genus of plant species that includes pinnately leafed herbs, shrubs, and shrubs. Preferably, the species used in accordance with the present invention is Artemisia annua, an aromatic branched herbaceous plant. The extract obtained from this plant can be derived from the whole plant or the aerial parts, and can be a dry, aqueous, and / or alcoholic extract.

[0048] Preferably, the composition for use according to the invention contains: - 0.5 to 3% by weight of a composition of Artemisia extract.

[0049] Preferably, the composition for use according to the invention contains: - 0.01 to 8% by weight of a composition of Echinacea extract, and / or - 0.01 to 7% by weight of a propolis composition, and / or - 0.5 to 3% by weight of a composition of Artemisia extract, and / or - 0.01 to 10% by weight of a composition of Allium sativum extract, and / or - 1 to 9% by weight of an extract of primula flowers with calyx.

[0050] According to the invention, preferably the composition for use according to the invention contains at least one other dermatologically and / or pharmaceutically acceptable agent.

[0051] According to one embodiment, the composition used according to the invention is intended for use as a medicament for the prevention and / or treatment of inflammation caused by Staphylococcus aureus.

[0052] Staphylococcus aureus is a Gram-positive bacterium characterized by rapidly increasing antibiotic resistance ( Tatiya-Aphiradee et al., 2019 ).

[0053] Preferably, the compositions for use according to the present invention may be administered orally, intravenously, subcutaneously, nasally, ophthalmically, auricularly, rectally, vaginally, by the respiratory route, or by application to the skin.

[0054] Even more preferably, the oral route can take the form of tablets, syrups, drinkable solutions or suspensions, capsules, preferably tablets.

[0055] Even more preferably, the intravenous route can be in the form of a solution.

[0056] Even more preferably, the subcutaneous route can be in the form of a solution.

[0057] Preferably, administration is by epicutaneous application.

[0058] Even more preferably, the route of application on the skin can take the form of an ointment, cream, patch, liquid solution or gel.

[0059] Even more preferably, the route of application on the skin takes the form of a cream, or liquid solution.

[0060] Preferably, the compositions for use according to the present invention are administered by the respiratory or nasal route in the form of nasal drops, nasal sprays, nasal powders, aerosols, such as compressed gas nasal aerosols and / or sprays, or nebulizers.

[0061] Advantageously, if the composition is suitable for nasal or respiratory administration, it may be advantageous to target the bronchopulmonary or paranasal sinuses.

[0062] Preferably, the compositions for use according to the present invention are administered to the nasal cavity by aerosol.

[0063] Compositions according to the invention can be administered to a patient daily, once a day, twice a day, three times a day or more times per day.

[0064] Preferably, the compositions according to the invention are administered to the patient once daily.

[0065] The compositions according to the invention may also comprise a physiologically acceptable medium, ie a medium that is compatible with the skin or with the various administration methods considered.

[0066] According to one embodiment of the present invention, the composition comprises, by weight of the composition: - Pharmaceutical grade purified water: sufficient quantity - 20mg total silver, consisting of up to 20% ionic and 80% colloidal silver, with an average particle size of 0.8nm - 0.9% Elderberry Extract - 5% St. John's wort extract - 1.5% Pelargonium sidoides dry extract - 3% Echinacea dry extract - 4% purified propolis extract.

[0067] According to one embodiment of the present invention, the composition comprises, by weight of the composition: - Pharmaceutical grade purified water: sufficient quantity - 20mg total silver, consisting of up to 20% ionic silver and 80% colloidal silver, with an average particle size of 0.8nm - 0.9% Elderberry Extract - 5% dried primula flower extract with calyx - 5% St. John's wort extract - 1.5% Pelargonium sidoides dry extract - 3% Echinacea dry extract - 4% purified propolis extract.

[0068] According to one embodiment of the present invention, the composition comprises, by weight of the composition: - 20mg total silver, consisting of up to 20% ionic silver and 80% colloidal silver, with an average particle size of 0.8nm - 0.9% Elderberry Extract - 5% St. John's wort dry extract - 1.5% Pelargonium sidoides dry extract - 3% Echinacea dry extract - 4% purified propolis extract.

[0069] According to a second aspect, the present invention relates to a cosmetic or dermatological composition comprising: - Colloidal form of silver - Elderberry extract - Hypericum perforatum extract - Pelargonium sidoides extract.

[0070] Preferably, the cosmetic or dermatological composition according to the invention contains: - 20 mg to 250 mg of silver in colloidal form per liter of composition.

[0071] Preferably, the cosmetic or dermatological composition according to the invention contains: - 0.3 to 5% by weight of an extract of elderberry.

[0072] Preferably, the cosmetic or dermatological composition according to the invention contains: - 0.5 to 11% by weight of a composition of extract of St. John's wort.

[0073] Preferably, the cosmetic or dermatological composition according to the invention contains: - 1 to 6% by weight of a composition of Pelargonium sidoides extract.

[0074] According to one embodiment, the cosmetic or dermatological composition according to the invention contains: - 20 mg to 250 mg of colloidal silver per liter of composition - 0.3 to 5% by weight of elderberry extract - 0.5 to 11% by weight of a composition containing an extract of St. John's wort - 1 to 6% by weight of a composition of Pelargonium sidoides extract.

[0075] According to one embodiment, the cosmetic or dermatological composition according to the invention further contains: - Silver in ionic form.

[0076] According to one embodiment, said cosmetic or dermatological composition according to this latter embodiment contains: - The total amount of silver per liter of composition is 20mg to 250mg, distributed as follows: i. 70-99.99% of the total weight of silver in colloidal form ii. Silver in ionic form, 0.01 to 30% of the total weight of silver.

[0077] According to one embodiment, the cosmetic or dermatological composition contains: - The total amount of silver per liter of composition is 20mg to 250mg, distributed as follows: i. 70-99.99% of the total weight of silver in colloidal form ii. 0.01 to 30% of the total weight of silver in ionic form - 0.3 to 5% by weight of elderberry extract - 0.5 to 11% by weight of a composition containing an extract of St. John's wort - 1 to 6% by weight of a composition of Pelargonium sidoides extract.

[0078] According to one embodiment, the cosmetic or dermatological composition according to the invention further contains: - Echinacea extract, and / or - Propolis and / or - Artemisia extract, and / or - Extract of Allium sativum, and / or - Extract of Primula flowers with calyx.

[0079] Preferably, the cosmetic or dermatological composition according to the invention contains: - 1 to 9% by weight of an extract of primula flowers with calyx.

[0080] Preferably, the cosmetic or dermatological composition according to the invention contains: - 0.01 to 8% by weight of an Echinacea extract.

[0081] Preferably, the cosmetic or dermatological composition according to the invention contains: - 0.01 to 10% by weight of an Allium sativum extract.

[0082] Preferably, the cosmetic or dermatological composition according to the invention contains: - 0.01 to 7% by weight of a propolis composition.

[0083] Preferably, the cosmetic or dermatological composition according to the invention contains: - 0.5 to 3% by weight of a composition of Artemisia extract.

[0084] Preferably, the cosmetic or dermatological composition according to the invention contains: - 0.01 to 8% by weight of a composition of Echinacea extract, and / or - 0.01 to 7% by weight of a propolis composition, and / or - 0.5 to 3% by weight of a composition of Artemisia extract, and / or - 0.01 to 10% by weight of a composition of Allium sativum extract, and / or - 1 to 9% by weight of an extract of primula flowers with calyx.

[0085] According to one embodiment of the present invention, the cosmetic or dermatological composition comprises, by weight of the composition: - Pharmaceutical grade purified water: sufficient quantity - 20mg total silver, consisting of up to 20% ionic silver and 80% colloidal silver, with an average particle size of 0.8nm - 0.9% Elderberry Extract - 5% St. John's wort extract - 1.5% Pelargonium sidoides dry extract - 3% Echinacea dry extract - 4% purified propolis extract.

[0086] According to one embodiment of the present invention, the cosmetic or dermatological composition comprises, by weight of the composition: - Pharmaceutical grade purified water: sufficient quantity - 20mg total silver, consisting of up to 20% ionic silver and 80% colloidal silver, with an average particle size of 0.8nm - 0.9% Elderberry Extract - 5% dried primula flower extract with calyx - 5% St. John's wort extract - 1.5% Pelargonium sidoides dry extract - 3% Echinacea dry extract - 4% purified propolis extract.

[0087] According to one embodiment of the present invention, the cosmetic or dermatological composition comprises, by weight of the composition: - 20mg total silver, consisting of up to 20% ionic silver and 80% colloidal silver, with an average particle size of 0.8nm - 0.9% Elderberry Extract - 5% St. John's wort dry extract - 1.5% Pelargonium sidoides dry extract - 3% Echinacea dry extract - 4% purified propolis extract.

[0088] By "non-therapeutic cosmetic or dermatological compositions" is understood, according to the present invention, an application intended for healthy individuals, not for the treatment of patients. In fact, the cosmetic compositions according to the present invention do not act as medicines for the treatment of diseases, but rather make it possible to improve the appearance of the surface of inflamed skin. Within the scope of the present invention, the cosmetic compositions make it possible to reduce the visual signs of inflammation.

[0089] Preferably, said cosmetic or dermatological composition comprises at least one cosmetically or dermatologically acceptable excipient.

[0090] By "cosmetically or dermatologically acceptable" is understood, according to the present invention, an excipient that is useful for the preparation of a cosmetic or dermatological composition and that is generally safe, non-toxic and not biologically or otherwise undesirable, and that is acceptable for cosmetic or dermatological use, in particular for application to the skin.

[0091] By "extract" is understood according to the invention a preparation obtained from the mentioned plant. Preferably, said extract is obtained using a solvent.

[0092] By "dry extract" is understood an extract from which the solvent has evaporated, ie an extract in which only the active ingredient or ingredients of the plant remain.

[0093] The cosmetic or dermatological compositions according to the invention can therefore be provided in the forms usually known for topical application, namely lotions, shampoos, balms, mousses, gels, dispersions, emulsions, sprays, serums, masks, liquid solutions, creams or sticks, in particular comprising, for the part, excipients which allow, inter alia, penetration to improve the properties and accessibility of the main active ingredients.

[0094] According to a third aspect, the present invention relates to the non-therapeutic cosmetic or dermatological use in a healthy individual of a composition comprising: - silver in colloidal form, - Elderberry extract, - Hypericum perforatum extract, - Pelargonium sidoides extract.

[0095] Preferably, said composition for cosmetic or dermatological use according to the invention contains: - 20 mg to 250 mg of silver in colloidal form per liter of composition.

[0096] Preferably, said composition for cosmetic or dermatological use according to the invention contains: - 0.3 to 5% by weight of an extract of elderberry.

[0097] Preferably, said composition for cosmetic or dermatological use according to the invention contains: - 0.5 to 11% by weight of a composition of extract of St. John's wort.

[0098] Preferably, said composition for cosmetic or dermatological use according to the invention contains: - 1 to 6% by weight of a composition of Pelargonium sidoides extract.

[0099] According to one embodiment, said composition for cosmetic or dermatological use according to the invention contains: - 20 mg to 250 mg of colloidal silver per liter of composition - 0.3 to 5% by weight of elderberry extract - 0.5 to 11% by weight of a composition containing an extract of St. John's wort - 1 to 6% by weight of a composition of Pelargonium sidoides extract.

[0100] According to one embodiment, said composition for cosmetic or dermatological use according to the invention additionally contains: - Silver in ionic form.

[0101] According to one embodiment, said composition of this cosmetic or dermatological use according to this latter embodiment contains: - The total amount of silver per liter of composition is 20mg to 250mg, distributed as follows: i. 70-99.99% of the total weight of silver in colloidal form ii. Silver in ionic form, 0.01 to 30% of the total weight of silver.

[0102] According to one embodiment, said composition for cosmetic or dermatological use contains: - The total amount of silver per liter of composition is between 20 mg and 250 mg, distributed as follows: i. 70-99.99% of the total weight of silver in colloidal form ii. 0.01 to 30% of the total weight of silver in ionic form - 0.3 to 5% by weight of elderberry extract - 0.5 to 11% by weight of a composition containing an extract of St. John's wort - 1 to 6% by weight of a composition of Pelargonium sidoides extract.

[0103] According to one embodiment, said composition for cosmetic or dermatological use according to the invention additionally contains: - Echinacea extract, and / or - Propolis, and / or - Artemisia extract, and / or - Extract of Allium sativum, and / or - Extract of Primula flowers with calyx.

[0104] Preferably, said composition for cosmetic or dermatological use according to the invention contains: - 1 to 9% by weight of an extract of primula flowers with calyx.

[0105] Preferably, said composition for cosmetic or dermatological use according to the invention contains: - 0.01 to 8% by weight of an Echinacea extract.

[0106] Preferably, said composition for cosmetic or dermatological use according to the invention contains: - 0.01 to 10% by weight of an Allium sativum extract.

[0107] Preferably, said composition for cosmetic or dermatological use according to the invention contains: - 0.01 to 7% by weight of a propolis extract.

[0108] Preferably, said composition for cosmetic or dermatological use according to the invention contains: - 0.5 to 3% by weight of a composition of Artemisia extract.

[0109] Preferably, said composition for cosmetic or dermatological use according to the invention contains: - 0.01 to 8% by weight of a composition of Echinacea extract, and / or - 0.01 to 7% by weight of a propolis composition, and / or - 0.5 to 3% by weight of a composition of Artemisia extract, and / or - 0.01 to 10% by weight of a composition of Allium sativum extract, and / or - 1 to 9% by weight of an extract of primula flowers with calyx.

[0110] According to one embodiment of the present invention, this cosmetic use makes it possible to reduce the visual signs of inflammation.

[0111] "Reducing the visual signs of inflammation" is understood to mean that in healthy individuals who show mild visual signs of inflammation, such as redness, the cosmetic composition according to the present invention makes it possible to reduce these visible signs. In such cases, the cosmetic composition according to the present invention acts precisely on the visual signs of inflammation.

[0112] According to one embodiment of the present invention, this cosmetic use makes it possible to prevent and / or reduce the intensity of redness of the skin and / or to lighten and / or even out the complexion and / or to mask superficial redness in healthy individuals.

[0113] According to one embodiment of the present invention, the composition for cosmetic or dermatological use comprises, by weight of the composition: - Pharmaceutical grade purified water: sufficient quantity - 20mg total silver, consisting of up to 20% ionic silver and 80% colloidal silver, with an average particle size of 0.8nm - 0.9% Elderberry Extract - 5% St. John's wort extract - 1.5% Pelargonium sidoides dry extract - 3% Echinacea dry extract - 4% purified propolis extract.

[0114] According to one embodiment of the present invention, the composition for cosmetic or dermatological use comprises, by weight of the composition: - Pharmaceutical grade purified water: sufficient quantity - 20mg total silver, consisting of up to 20% ionic silver and 80% colloidal silver, with an average particle size of 0.8nm - 0.9% Elderberry Extract - 5% dried primula flower extract with calyx - 5% St. John's wort extract - 1.5% Pelargonium sidoides dry extract - 3% Echinacea dry extract - 4% purified propolis extract.

[0115] According to one embodiment of the present invention, the composition for cosmetic or dermatological use comprises, by weight of the composition: - 20mg total silver, consisting of up to 20% ionic silver and 80% colloidal silver, with an average particle size of 0.8nm - 0.9% Elderberry Extract - 5% St. John's wort dry extract - 1.5% Pelargonium sidoides dry extract - 3% Echinacea dry extract - 4% purified propolis extract.

[0116] According to a fourth aspect, the present invention relates to a method for treating inflammation, preferably caused by Staphylococcus aureus, comprising administering to a person in need thereof an effective amount of a composition according to the present invention.

[0117] According to a fifth aspect, the present invention relates to a method for preparing a cosmetic or dermatological composition according to the invention, comprising at least the step of mixing the ingredients to be contained in the composition.

[0118] Unless otherwise indicated, percentages throughout this specification and in the following examples are by weight, and ranges of values ​​expressed in the form "...to..." include the stated lower and upper limits. The following examples are provided by way of illustration, not limitation, of the scope of the invention.

[0119] The following examples are intended to illustrate the present invention but not to limit its scope. [Brief explanation of the drawings]

[0120] [Figure 1]1 is a histogram chart showing IL-8 concentrations (pg / ml) after various treatments: 1 - composition according to Example 1 (in liquid solution), 2 - composition according to Example 1 (in liquid solution) + Staphylococcus aureus, 3 - composition according to Example 1 in cream form, 4 - composition according to Example 1 in cream form + Staphylococcus aureus. Data obtained from at least three independent experiments. [Figure 2] 1 is a histogram chart showing IP-10 concentrations (pg / ml) after various treatments: 1 - composition according to Example 1 (in liquid solution), 2 - composition according to Example 1 (in liquid solution) + Staphylococcus aureus, 3 - composition according to Example 1 in cream form, 4 - composition according to Example 1 in cream form + Staphylococcus aureus. Data obtained from at least three independent experiments. [Figure 3] 1 is a histogram chart showing IL-1β concentrations (pg / ml) after various treatments: 1 - composition according to Example 1 (in liquid solution), 2 - composition according to Example 1 (in liquid solution) + Staphylococcus aureus, 3 - composition according to Example 1 in cream form, 4 - composition according to Example 1 in cream form + Staphylococcus aureus. Data obtained from at least three independent experiments. [Figure 4] 1 is a histogram chart showing IL-6 concentrations (pg / ml) after various treatments: 1 - composition according to Example 1 (in liquid solution), 2 - composition according to Example 1 (in liquid solution) + Staphylococcus aureus, 3 - composition according to Example 1 in cream form, 4 - composition according to Example 1 in cream form + Staphylococcus aureus. Data obtained from at least three independent experiments. DETAILED DESCRIPTION OF THE INVENTION

[0121] Example 1: Example compositions

[0122] The composition contains the following per 100 mL of composition: - 20mg total silver, consisting of up to 20% ionic silver and 80% colloidal silver, with an average particle size of 0.8nm - 0.9% Elderberry Extract - 5% St. John's wort dry extract - 1.5% Pelargonium sidoides dry extract - 3% Echinacea dry extract - 4% purified propolis extract

[0123] Example 2: Anti-inflammatory activity of the composition of Example 1.

[0124] material and method The human epithelial cell line HT-29 was cultured as a monolayer in DMEM (Dulbecco's Modified Eagle's Medium, Gibco, UK) supplemented with 10% fetal bovine serum at 37°C and 5% CO. At approximately 90% of the monolayer, cells were incubated with a 0.25% trypsin solution and 10 mM EDTA for 10 min at 37°C.

[0125] To determine the anti-inflammatory effect, eukaryotic cells were cultured at 2 x 10 5 The cells were cultured at a concentration of 100 cells / ml. The medium was changed every 2 days for a total of 14 days to promote not only monolayer formation (3-4 days) but also cell receptor maturation. The resulting monolayer was washed twice with phosphate-buffered saline (PBS).

[0126] DMEM medium (1 ml) containing various preparations was added to each well and incubated for 20 hours at 37° C. The preparations were as follows: - Control DMEM -Staphylococcus aureus 1 x 10 5 DMEM containing CFU / ml DMEM containing 10% of the composition according to Example 1 (liquid solution) 10% of the composition according to Example 1 (liquid solution) and 1 x 10 Staphylococcus aureus 5 DMEM containing CFU / ml DMEM containing 10% of the composition according to Example 1 in cream form 10% of the composition according to Example 1 in cream form and 1 x 10 Staphylococcus aureus 5 DMEM containing CFU / ml

[0127] After incubation, cell-free supernatants were used to determine cytokine expression: IL-8, IP-10, IL-1β, and IL-6 were assessed by ELISA (enzyme-linked immunosorbent assay) according to the manufacturer's instructions (Diaclone, USA).

[0128] result These results indicate that S. aureus elevates the concentrations of inflammatory cytokines compared to untreated cell line samples in DMEM medium. Approximately three-fold increases were measured for IL-8 (Figure 1) and IP-10 (Figure 2). Approximately two-fold elevated levels were observed for IL-1β (Figure 3). The lowest increase, approximately 1.5-fold, was obtained for IL-6 (Figure 4). This result indicates that IL-8 and IP-10 are the most sensitive markers of inflammation caused by S. aureus in these experiments.

[0129] The data showed that there was no overexpression of IL-8 after treatment with the two compositions according to the invention, in cream or liquid solution form (Figure 1). No overexpression was measured after application of the products to cell lines in an inflammatory state caused by Staphylococcus aureus. The measured levels were similar.

[0130] The next marker analyzed was IP-10. The data showed that when the composition according to Example 1 was not in cream form (i.e., in liquid solution form), better protection, expressed as inhibition of IP-10 overexpression, was observed after its application compared to the cream (Figure 2).

[0131] The same was observed for IL-1β, another marker analyzed, with a 60-fold reduction (Figure 3). The composition according to Example 1 in cream form reduced the induction of IL-1β by approximately 1.5-fold.

[0132] The most significant reduction in IL-6 was obtained after application of the composition according to Example 1 in cream form, which was approximately 9-fold (Figure 4). The reduction in IL-6 after application of the composition according to Example 1 was calculated to be approximately 6-fold.

[0133] Consideration These results show that the two preparations (the composition according to Example 1 in the form of a liquid solution and the composition according to Example 1 in the form of a cream) reduce the concentrations of four inflammatory cytokines in two cases: - control sample (DMEM), and -Cell lineages in inflammatory conditions caused by Staphylococcus aureus

[0134] Based on the reported data, it can be concluded that the ability of the composition according to Example 1 in the form of a liquid solution to reduce the concentrations of IL-8, IP-10 and IL-1β is greater than the effect of the composition according to Example 1 in the form of a cream. On the other hand, with regard to IL-6, the effect of the composition according to Example 1 in the form of a cream was revealed to be more pronounced than that of the composition according to Example 1 in the form of a non-cream (liquid solution).

[0135] [References] -Agarwal, H., & Shanmugam, V. (2020). A review on anti-inflammatory activity of green synthesized zinc oxide nanoparticles: Mechanism-based approach. Bioorganic chemistry, 94, 103423. -Al-Daghri, N. M., Yakout, S., Al-Shehri, E., Al-Fawaz, H., Aljohani, N., & Al-Saleh, Y. (2014). Inflammatory and bone turnover markers in relation to PTH and vitamin D status among Saudi postmenopausal women with and without osteoporosis. International journal of clinical and experimental medicine , 7(9), 2812. -Dinarello, CA. Interleukin-1. Cytokine Growth Factor Rev 1997. 8:253-265. -Greten, F. R., & Grivennikov, S. I. (2019). Inflammation and cancer: triggers, mechanisms, and consequences. Immunity, 51(T), 27-41. -Gunalan, G., Vijayalakshmi, K., Saraswathy, A., Hopper, W., & Tamilvannan, T. (2014). Antiinflammatory activities of phytochemicals from Bauhinia variegata Linn, leaf: An in silico approach. J. chem. pharm, 6(9), 334-48. -Kolb, M., Margetts, P. J., Anthony, D. C., Pitossi, F., & Gauldie, J. (2001). Transient expression of IL- Iβ induces acute lung injury and chronic repair leading to pulmonary fibrosis. The Journal of clinical investigation, 107(12), 1529-1536. -Liu, Q., Mazhar, M., & Miller, L. S. (2018). Immune and inflammatory reponses to Staphylococcus aureus skin infections. Current dermatology reports, 7(4), 338-349. -Medzhitov, R. (2008). Origin and physiological roles of inflammation. Nature, 454(7203), 428- 435. -Mueller, M., Hobiger, S., & Jungbauer, A. (2010). Anti-inflammatory activity of extracts from fruits, herbs and spices. Food chemistry, 122(4), 987-996. -Pathak, S., Goldofsky, E., Vivas, E. X., Bonagura, V. R., & Vambutas, A. (2011). IL- Iβ is overexpressed and aberrantly regulated in corticosteroid nonresponders with autoimmune inner ear disease. The Journal of Immunology, 186(3), 1870-1879. -Peiro, C., Lorenzo,O., Carraro, R., & Sanchez-Ferrer, C. F. (2017). IL- Iβ inhibition in cardiovascular complications associated to diabetes mellitus. Frontiers in pharmacology, 8, 363. -Sims, J. E., and D. E. Smith. 2010. The IL-1 family: regulators of immunity. Nat. Rev. Immunol. 10: 89-102. -Singh, J. K., Simoes, B. M., Howell, S. J., Farnie, G., & Clarke, R. B. (2013). Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Research, 15(4), 1-9. -Tatiya-Aphiradee, N., Chatuphonprasert, W., & Jarukamjorn, K. (2019). Anti-inflammatory effect of Garcinia mangostana Linn, pericarp extract in methicillin-resistant Staphylococcus aureus-induced superficial skin infection in mice. Biomedicine & Pharmacotherapy, 111, 705- 713.

Claims

1. A composition for use as a medicament for the prevention and / or treatment of inflammation, comprising: - Colloidal silver Elderberry (Sambucus Nigra) extract - Hypericum perforatum extract - Pelargonium sidoides extract.

2. 2. A composition for use according to claim 1, characterized in that said silver in colloidal form has a particle size of between 0.1 and 30 nanometers.

3. A composition for use according to claim 1 or 2, comprising: - 20 mg to 250 mg of silver in colloidal form per liter of composition - 0.3 to 5% by weight of a composition of elderberry extract - 0.5 to 11% by weight of a composition of St. John's wort extract - 1 to 6% by weight of a composition of Pelargonium sidoides extract.

4. 3. The composition for use according to claim 1 or 2, further comprising: - Silver in ionic form.

5. 5. The composition for pharmaceutical use of claim 4, comprising: - A total amount of silver between 20 mg and 250 mg per liter of composition, distributed among: i. 70-99.99% of the total weight of silver in colloidal form ii. 0.01 to 30% of the total weight of silver in ionic form - 0.3 to 5% by weight of a composition of elderberry extract - 0.5 to 11% by weight of a composition of St. John's wort extract - 1 to 6% by weight of a composition of Pelargonium sidoides extract.

6. 6. The composition for use according to any one of claims 1 to 5, further comprising: Echinacea extract, and / or - propolis, and / or Artemisia extract, and / or - Allium sativum extract, and / or - Primula flower extract with calyx.

7. 7. A composition for use according to claim 6, comprising: - 0.01 to 8% by weight of a composition of Echinacea extract, and / or - 0.01 to 7% by weight of a composition of propolis, and / or - 0.5 to 3% by weight of a composition of Artemisia extract, and / or - 0.01 to 10% by weight of a composition of Allium sativum extract, and / or - 1 to 9% by weight of a composition of extract of Primula flowers with calyx.

8. A composition for use according to any one of claims 1 to 7 for use as a medicament for the prevention and / or treatment of inflammation caused by Staphylococcus aureus.

9. 9. A composition for use according to any one of claims 1 to 8, characterized in that it is in a form suitable for administration by application onto the skin in the form of an ointment, cream, liquid solution, patch or gel, preferably a cream or liquid solution.

10. 1. Non-therapeutic cosmetic use of a composition for reducing visual signs of inflammation on the skin of a subject, comprising: - silver in colloidal form, Elderberry extract, - Hypericum perforatum extract, - Pelargonium sidoides extract.

Images